캅토프릴

캅토프릴
캅토프릴 구조식 이미지
카스 번호:
62571-86-2
한글명:
캅토프릴
동의어(한글):
캅토프릴
상품명:
Captopril
동의어(영문):
on;acidic;captoril;(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid;capoten;(2S)-1-[(2S)-3-Mercapto-2-methylpropionyl]-2-pyrrolidinecarboxylic acid;Timolo;Captopril API;CAPTOPRIL USP;cysteine-rich
CBNumber:
CB6206769
분자식:
C9H15NO3S
포뮬러 무게:
217.29
MOL 파일:
62571-86-2.mol
MSDS 파일:
SDS

캅토프릴 속성

녹는점
104-108 °C (lit.)
끓는 점
427.0±40.0 °C(Predicted)
알파
-129.5 º (c=1, EtOH)
밀도
1.2447 (rough estimate)
굴절률
-127.5 ° (C=1.7, EtOH)
저장 조건
room temp
용해도
H2O: 0.1 g/mL, 매우 약간 흐릿함, 무색
물리적 상태
결정성 분말
산도 계수 (pKa)
3.7, 9.8(at 25℃)
색상
흰색에서 황백색까지
생물학적 소스
synthetic (organic)
광학 활성
-112.8°(C=0.01g/ml ETOH)
수용성
녹는
Merck
14,1774
BRN
477887
BCS Class
3
안정성
안정적인. 강한 산화제와 호환되지 않습니다.
InChI
1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
InChIKey
FAKRSMQSSFJEIM-RQJHMYQMSA-N
SMILES
C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
CAS 데이터베이스
62571-86-2(CAS DataBase Reference)
NIST
Captopril(62571-86-2)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn,Xi
위험 카페고리 넘버 43-63-36/37/38-40
안전지침서 36/37-37/39-26-36-22
WGK 독일 2
RTECS 번호 UY0550000
HS 번호 29339900
스토리지 클래스 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects
Hazard Classifications Muta. 2
Repr. 1B
유해 물질 데이터 62571-86-2(Hazardous Substances Data)
독성 LD50 in mice (mg/kg): 1040 i.v.; 6000 orally (Keim)
기존화학 물질 KE-23097
그림문자(GHS): Health Hazard (GHS08)
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H341 유전적인 결함을 일으킬 것으로 의심됨 (노출되어도 생식세포 유전독성을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 생식세포 변이원성 물질 구분 2 경고 P201,P202, P281, P308+P313, P405,P501
예방조치문구:
P201 사용 전 취급 설명서를 확보하시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
NFPA 704
0
2 0

캅토프릴 MSDS


Captopril

캅토프릴 C화학적 특성, 용도, 생산

개요

Captopril is the most studied of the angiotensin-converting enzyme inhibitors proposed as an antihypertensive drug. It blocks angiotensin-converting enzyme, which suppresses formation of angiotensin II and relieves its vasoconstricting effect on arterial and venous vessels. Overall vascular peripheral tension is reduced, which results in the lowering of arterial pressure.

화학적 성질

White or almost white, crystalline powder.

용도

Captopril has also been shown to inhibit the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density. Captopril demonstrates noncompetitive inhibition of tyrosinase monophenolase activity and competitive inhibition of diphenolase activity

정의

ChEBI: A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.

Biological Functions

Captopril (Capoten) is an orally effective ACE inhibitor with a sulfhydryl moiety that is used in binding to the active site of the enzyme. Captopril blocks the blood pressure responses caused by the administration of angiotensin I and decreases plasma and tissue levels of angiotensin II.

일반 설명

Captopril, 1-[(2S)-3-mercapto-2-methyl-1-oxopropionyl]proline (Capoten), blocks the conversion of angiotensinI to angiotensin II by inhibiting the convertingenzyme. The rational development of captopril as an inhibitorof ACE was based on the hypothesis that ACE and carboxypeptidaseA functioned by similar mechanisms. It wasnoted that d-2-benzylsuccinic acid was a potent inhibitor ofcarboxypeptidase A, but not ACE. By use of this small molecule as a prototype, captopril was designed with a carboxylgroup on a proline and a thiol group was introduced toenhance the binding to the zinc ion of ACE. The importantbinding points at the active site of ACE are thought to be anarginine residue, which provides a cationic site that attracts acarboxylate ion, and a zinc ion, which can polarize a carbonylgroup of an amide function to make it more susceptible to hydrolysis.Hydrophobic pockets lie between these groups in theactive site, as does a functional group that forms a hydrogenbond with an amide carbonyl.

부작용

Approximately 10% of the patients treated with captopril report a dose-related maculopapular rash that often disappears when the dosage of captopril is reduced. Other common adverse effects are fever, a persistent dry cough (incidence as high as 39%), initial dose hypotension, and a loss of taste that may result in anorexia. These effects are reversed when drug therapy is discontinued. More serious toxicities include a 1% incidence of proteinuria and glomerulonephritis; less common are leukopenia and agranulocytosis. Since food reduces the bioavailability of captopril by 30 to 40%, administration of the drug an hour before meals is recommended. All converting enzyme inhibitors are contraindicated in patients with bilateral renal artery disease or with unilateral renal artery disease and one kidney. Use under these circumstances may result in renal failure or paradoxical malignant hypertension.

신진 대사

The onset of action following oral administration of captopril is about 15 minutes, with peak blood levels achieved in 30 to 60 minutes. Its apparent biological half-life is approximately 2 hours, with its antihypertensive effects observed for 6 to 10 hours. The kidneys appear to play a major role in the inactivation of captopril.

Purification Methods

Purify it by recrystallisation from EtOAc/hexane. It is also purified by dissolving in EtOAc and chromatographed on a column of Wakogel C200 using a linear gradient of MeOH in EtOAc (0-100o) and fractions which give a positive nitroprusside test (for SH), are combined, evaporated and recrystallised from EtOAc/hexane (1:1), to give white crystals with [] D -128.2o (c 2.0, EtOH). [Nam J Pharm Sci 73 1843 1984]. Alternatively, dissolve it in H2O, apply to a column of AG-50Wx2 (BioRad) and elute with H2O. The free acid is converted to the dicyclohexylamine salt in MeCN by addition of the amine until the pH is 8-9. The salt is converted to the free acid by shaking with EtOAc and 10% aqueous KHSO4 or passage through an AG50Wx2 column. The EtOAc solution is dried (MgSO4), evaporated to dryness and the residue is recrystallised as above from EtOAc/hexane [Cushman et al. Biochemistry 16 5484 1977, NMR and IR: Horii & Watanabe Yakugaku Zasshi (J Pharm Soc Japan) 81 1786 1961]. It is an antihypertensive because it is a potent competitive inhibitor of the angiotensive convertive enzyme (ACE-inhibitor) with a Ki value of 0.0017\M [Shimazaki et al. Chem Pharm Bull Jpn 30 3139 1982].

캅토프릴 준비 용품 및 원자재

원자재

준비 용품


캅토프릴 공급 업체

글로벌( 611)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hubei Aiputi Bioengineering Co., Ltd. 17762444226
d17762444226@163.com China 2400 58
Zhengzhou Baiyu Pharmaceutical Co., Ltd 13938569199
baiyu@163.cn China 391 58
Hubei Weideli Chemical Reagent Co.,Ltd. 181-6332-1995 18062128043
18163321995@163.com China 4800 58
Hubei Weideli Chemical Reagent Co., Ltd. 027-83984790 17720532645
t17720532645@163.com China 963 58
J & K SCIENTIFIC LTD. 18210857532 18210857532
jkinfo@jkchemical.com China 96815 76
Meryer (Shanghai) Chemical Technology Co., Ltd. 4006356688 18621169109
market03@meryer.com China 40202 62
3B Pharmachem (Wuhan) International Co.,Ltd. 18930552037
3bsc@sina.com China 15813 69
TCI (Shanghai) Development Co., Ltd. 021-67121386
Sales-CN@TCIchemicals.com China 24512 81
Beijing HwrkChemical Technology Co., Ltd 89508211 18501085097
sales.bj@hwrkchemical.com China 9409 55
Beijing Ouhe Technology Co., Ltd 13552068683 13522913783
2355560935@qq.com China 11777 60

캅토프릴 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved